Biodesix (BDSX)
NASDAQ:BDSX
Want to see BDSX full AI Analyst Report?
BDSX Stock Chart & Stats
$13.14
-$0.03(-2.01%)
At close: 4:00 PM EST
$13.14
-$0.03(-2.01%)
Day’s Range― - ―
52-Week Range$3.42 - $20.21
Previous CloseN/A
Volume171.18K
Average Volume (3M)107.55K
Market Cap
$151.63M
Enterprise Value$159.30M
Total Cash (Recent Filing)$18.99M
Total Debt (Recent Filing)$72.85M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Aug 12, 2026EPS Estimate
-0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.77
Shares Outstanding10,108,580
10 Day Avg. Volume48,205
30 Day Avg. Volume107,552
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-20.83
Price to Sales (P/S)0.58
P/FCF Ratio-2.17
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue1.80
Enterprise Value/Gross Profit2.22
Enterprise Value/Ebitda-7.25
Forecast
1Y Price Target
$30.67Price Target Upside133.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-3.07
Revenue Forecast (FY)$108.01M
Bulls Say, Bears Say
Bulls Say
Balance Sheet FlexibilityA capital raise together with an amended debt facility and an at-the-market program materially strengthened the balance sheet and reduced near-term financing pressure, improving flexibility for growth investments.
Commercial ExpansionExpansion and reconfiguration of the sales force combined with steady rep productivity is expected to deepen market penetration, increase test volumes, and support reimbursement gains.
Profitability ImprovementPositive adjusted EBITDA driven by higher test volumes and stronger revenue per test signals improving operating leverage and a clearer path toward profitability, which can attract value-oriented investors.
Bears Say
Clinical Study DelayA delayed clinical study readout due to required patient follow-up can postpone key data milestones and extend the timeline for potential product expansion, increasing uncertainty around catalysts.
Ongoing Cash BurnContinued substantial cash outflows and reliance on capital raises indicate persistent financing risk that could pressure the stock if access to funding tightens.
Revenue Quality And SeasonalityReported results boosted by collections from prior periods and test revenue seasonality tied to patient deductible dynamics raise the risk of sequential revenue declines after strong periods.
Biodesix News
BDSX FAQ
What was Biodesix’s price range in the past 12 months?
Biodesix lowest stock price was $3.42 and its highest was $20.21 in the past 12 months.
What is Biodesix’s market cap?
Biodesix’s market cap is $151.63M.
When is Biodesix’s upcoming earnings report date?
Biodesix’s upcoming earnings report date is Aug 12, 2026 which is in 96 days.
How were Biodesix’s earnings last quarter?
Biodesix released its earnings results on May 04, 2026. The company reported -$0.81 earnings per share for the quarter, beating the consensus estimate of -$1.13 by $0.32.
Is Biodesix overvalued?
According to Wall Street analysts Biodesix’s price is currently Undervalued.
Does Biodesix pay dividends?
Biodesix does not currently pay dividends.
What is Biodesix’s EPS estimate?
Biodesix’s EPS estimate is -0.92.
How many shares outstanding does Biodesix have?
Biodesix has 10,108,580 shares outstanding.
What happened to Biodesix’s price movement after its last earnings report?
Biodesix reported an EPS of -$0.81 in its last earnings report, beating expectations of -$1.13. Following the earnings report the stock price went up 32.564%.
Which hedge fund is a major shareholder of Biodesix?
Currently, no hedge funds are holding shares in BDSX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biodesix Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.67 (133.38% Upside)
$30.67 (133.38% Upside)
Hedge Fund Trend
Decreased
By 15.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-79.44%
12-Months-Change
Fundamentals
Return on Equity
-2101.40%
Trailing 12-Months
Asset Growth
9.74%
Trailing 12-Months
Company Description
Biodesix
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
BDSX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a clear positive trajectory: robust top-line growth (42% YoY), meaningful margin expansion (300 bps YoY), doubling of development services revenue, and improved profitability metrics (net loss and adjusted EBITDA both materially improved). Management raised full-year guidance and detailed a repeatable commercial expansion plan (salesforce growth, primary care adoption) supported by strong clinical evidence (large validation study). Remaining negatives are that the company is not yet profitable, operating expenses exceeded Q1 revenue due to planned commercial investment, development services revenue showed some timing-driven variability, and operational/logistics risks (weather/FedEx) and one-time items introduce some quarter-to-quarter noise. On balance, the highlights significantly outweigh the lowlights, indicating constructive momentum toward sustained growth and eventual profitability.View all BDSX earnings summariesBDSX Stock 12 Month Forecast
Average Price Target
$30.67
▲(133.38% Upside)